Clinical Trials in France / NCT06618924
Active, not recruiting
Observational
Digital Modeling of Thoracic CT and Pulmonary Fibrosis
NCT06618924 · tracked via the Priya Life Science France tracker
Condition(s) studied
Inspiration Expiration Thoracic TDM Sequences of Patients With Diffuse Interstitial Lung Disease (DIP)
Study summary
Currently, to our knowledge, there is little data on the combination of tools based on a similar concept to understand and evaluate ILDs. It is expected that this portfolio of multi-tool software implemented in radiology departments, applied to routine thoracic TDM, will provide additional qualitative and quantitative information in real time that will be of great help for diagnosis, prognosis prediction, and treatment decision-making in ILDs.
Eligibility
Inclusion criteria:
* Informed patients who have consented to participate in the research.
* Retrospective data from patients followed for ILDs who underwent two thoracic TDM scans in inspiration and expiration (IE-TDM) at least one year apart, meeting or not meeting the criteria for progressive fibrosis \[presence of two of the following criteria within one year of follow-up: 1/clinical worsening, 2/radiological evidence of disease progression between the two IE-TDM scans, 3/decline in FVC ≥5% or absolute decrease in DLCO (corrected for Hb) \> 10%\].
* 300 records, based on retrospective data, will constitute the initial AVICENNE database (500 records will be selected at Avicenne Hospital APHP so that 300 meet the quality criteria for inspiration/expiration thoracic TDM scans)
Exclusion criteria:
* Patients under 18 years of age.
* Patients under guardianship/curatorship.
* Patients under AME (State Medical Assistance).
Primary outcome measure(s)
- Qualitative and quantitative parameters obtained by in silico modeling of interstitial pattern, intra-pulmonary vascular remodeling and airway remodeling. — At 12 months after initial CT scan
Identify patients at risk of progressive and irreversible fibrosis and those who could respond to antifibrotic treatments, by developing the identification of qualitative and quantitative biomarkers from the numerical modeling of routine thoracic CT scans. - Specific mechanical parameters obtained by dynamic poromechanical modeling obtained by dynamic poromechanical modeling. — At 12 months after initial CT scan
Identify patients at risk of progressive and irreversible fibrosis and those who could respond to antifibrotic treatments, by developing the identification of qualitative and quantitative biomarkers from the numerical modeling of routine thoracic CT scans.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Hôpital Avicenne APHP | Bobigny | France |
More Assistance Publique - Hôpitaux de Paris trials in France
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06618924 on ClinicalTrials.gov ↗ ← All trials in France